BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, June 16, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

May 25, 2015

View Archived Issues

ASP-7147 shows promise in clinic for IBS-D

Read More

VPR-7 effective in murine IBD models

Read More

VBL Therapeutics discloses new drug candidate for liver fibrosis in NASH

Read More

U.S. scientists report anti-EFNA4 antibody-drug conjugates

Read More

Cypher Genomics and Celgene collaborate to discover novel genomic biomarkers

Read More

NIH extends grant to Viamet for antifungal agents for Valley fever

Read More

Baxter seeks European approval for IGSC 20% for primary immunodeficiencies

Read More

Sustained effects seen with ENV-905 Ophthalmic Implant in vivo

Read More

EMA committee recommends approval of Omidria

Read More

EMA committee hands down positive opinion for Keytruda in advanced melanoma

Read More

Merus and Selexis awarded grant to develop bispecific antibody combination products

Read More

EMA's CHMP supports approval of Repatha for high cholesterol

Read More

Stelara recommended for European approval for plaque psoriasis in adolescents

Read More

MSI-1 inhibitors block RNA binding as a new strategy for cancer treatment

Read More

Janssen to acquire license to Novo Nordisk autoimmune disease development program

Read More

Kuvan gets positive opinion from CHMP for expanded indication

Read More

Novel small-molecule disruptors of HuR-mRNA interaction show promise for cancer therapy

Read More

R-Tech Ueno completes single-dose phase I trial of RTU-1096

Read More

Bayer patents chymase inhibitors

Read More

Boehringer Ingelheim presents Brd4 inhibitors

Read More

iTeos Therapeutics discloses TDO2 inhibitors

Read More

Bristol-Myers Squibb prepares and tests GSK-3 inhibitors for Alzheimer's

Read More

Gilead Sciences patent describes development of antiviral compounds

Read More

Imbruvica recommended for European approval in Waldenstrom's macroglobulinemia

Read More

Amgen ends participation in collaboration on brodalumab development

Read More

Nivolumab receives EMA recommendation for squamous NSCLC

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 15, 2026.
  • Neck exam

    Ethyreal launches to treat the underlying cause of Graves’, TED

    BioWorld
    Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
  • Illustration of Lactobacillus

    Microbiota modulates the antidepressant effects of GLP-1 analogues

    BioWorld Science
    Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
  • Genome sequence map

    EHA 2026: With new lenses, a changing view on pediatric cancers

    BioWorld
    In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
  • Microscopic image of chronic myeloid leukemia

    Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid

    BioWorld
    Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing